C1-inhibitor (C1-INH) deficiency is a rare blood disorder resulting in angioedema attacks that are debilitating and may be life-threatening. Prophylaxis and therapy of events has changed since our first Canadian Consensus Conference on the diagnosis, therapy and management of HAE. We have formed the Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d’Angioédème Héréditaire (RCAH) – http://www.haecanada.com webcite to advance care of patients with this disorder in Canada. We here present a review of management of HAE in Canada.
The electronic version of this article is the complete one and can be found online at: http://www.aacijournal.com/content/6/1/20